Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1626 1629
This examiner grants 80% of resolved cases
Examiner SHTERENGARTS, SAMANTHA L works in Tech Center 1600 and Art Unit 1623. The examiner has a record of 1697 resolved cases. The allowance rate for these cases is 79.4 percent, which shows the frequency of patent grants. The median time to allowance is 782 days. This 782-day period is the timeframe for successful prosecution with this examiner, providing an expectation for applicants.
The interview lift is 8.0 percent, which indicates that interviews are associated with an increase in the likelihood of allowance. This 8.0 percent lift is smaller than the 79.4 percent baseline allowance rate, suggesting that many cases reach allowance without the need for an interview. However, the 8.0 percent lift still represents an impact on the prosecution outcome. With 1697 resolved cases, the 782-day median and the 8.0 percent lift provide a statistical foundation for practitioners in Art Unit 1623 within Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18279293 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Final Rejection | Mindset Pharma Inc. |
| 18076613 | FLUORINE-CONTAINING COMPOUND | Non-Final OA | DAIKIN INDUSTRIES, LTD. |
| 18846525 | ALOTAKETAL COMPOUNDS AND DERIVATIVES THEREOF FOR USE AS ANTIVIRAL AGENTS | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
| 18294814 | ALPHA-METHYLENE AND AMINOMETHYL LACTONES AND LACTAMS FOR TREATMENT OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) | Non-Final OA | Purdue Research Foundation |
| 17376829 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Non-Final OA | NOVARTIS PHARMA AG |
| 18841597 | CRYSTALS OF VITAMIN D DERIVATIVE OR CRYSTALS OF SOLVATE THEREOF | Non-Final OA | TEIJIN PHARMA LIMITED |
| 17594754 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | Final Rejection | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY |
| 18690087 | NEW QUINOLINE DERIVATIVES | Non-Final OA | ELANCO ANIMAL HEALTH GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy